Literature DB >> 22156309

Evidence for the involvement of 5-HT1A receptors in the mediation of exploratory locomotor activity in the rat.

C Johansson1, S Ahlenius.   

Abstract

The 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), 0.1 mg/kg(-1) subcutaneously, produced a suppression of horizontal ('locomotion') and vertical ('rearing') activity, in an open field arena. This effect was partially antagonized by treatment with (-)pindolol, 2 mg/kg(-1) subcutaneously. (-)Pindolol by itself produced a small, but statistically significant suppression of locomotor activity. There were no effects on rearing activity by (-)pindolol. In comparison with saline-treated controls, 8-OH-DPAT increased peripheral, relative to total, horizontal activity in the open field arena. (-)Pindolol adminis tration restored this pattern of activity to normal levels in 8-OH-DPAT-treated animals, without altering the relation peripheral to total activity by itself.

Entities:  

Year:  1989        PMID: 22156309     DOI: 10.1177/026988118900300106

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  3 in total

1.  Effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on locomotor activity and rearing of mice and rats.

Authors:  J L Evenden; K Angeby-Möller
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Effects of 8-OH-DPAT, buspirone and ICS 205-930 on feeding in a novel environment: comparisons with chlordiazepoxide and FG 7142.

Authors:  P J Fletcher; M Davies
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Effects of repeated treatment with the 5-HT1A and 5-HT1B agonists (R)-( +)-8-hydroxy-DPAT and CP-94253 on the locomotor activity and axillary temperatures of preweanling rats: evidence of tolerance and behavioral sensitization.

Authors:  Sanders A McDougall; Jordan A Taylor; Matthew J Roe; Constance J Greenwood
Journal:  Psychopharmacology (Berl)       Date:  2021-11-24       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.